MIMS guide to bipolar disorder and schizophrenia
Abstract
AI
AI
The guide focuses on bipolar disorder and schizophrenia, highlighting their clinical definitions, prevalence, and impact on individuals and society. Bipolar disorder is characterized by repeated episodes of mania and depression, whereas schizophrenia remains a leading cause of psychiatric hospitalizations. The document also discusses classification systems (ICD-10 and DSM-IV), provides diagnostic criteria, and mentions the importance of effective service provision and treatment strategies for these debilitating mental illnesses.
References (19)
- WHO. International statistical classification of diseases and related health problems. 10th revision (ICD-10). Geneva: WHO; 2007. Available from: www.who.int/classifications/apps/icd/icd10online.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM). 4th ed. Arlington (VA): APA; 2000.
- Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series. Medication treatment of bipolar disorder. Postgrad Med 2000;Spec No:1-104.
- Goodwin GM, Consensus Group of the British Association for Psycho- pharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-73.
- NICE. Electroconvulsive therapy (ECT). Technology appraisal 59. London: NICE; 2003. Available from: www.nice.org.uk/ta59.
- MIMS. June 2008
- BNF 55. London: BMJ Group/RPS Publishing; 2008.
- Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
- Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 1980;37:979-83.
- Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24:75-85.
- Lewis SW, Buchanan RW. Fast facts -schizophrenia. Oxford: Health Press; 2002.
- NICE. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology appraisal 43. London: NICE; 2002. Available from: www.nice.org.uk/ta43.
- Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
- Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-84.
- Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
- Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64 Suppl 16:24-33.
- Webb RT, Howard L, Abel KM. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2004;2.
- NICE. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: NICE; 2003. Available from: www.nice.org.uk/CG1.
- Taylor D, Paton C, Kerwin R. The Maudsley prescribing guidelines. 9th ed. London: Informa Healthcare; 2007.